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Abstract
Background: Adherence to antipsychotics for schizophrenia is associated with favorable clinical
outcomes. This study compared annual mental-health service utilization by recent medication
adherence levels for patients treated for schizophrenia, and assessed whether adherence levels
change from pre- to post-psychiatric hospitalization.
Methods: We analyzed data from a large prospective, non-interventional study of patients treated
for schizophrenia in the United States, conducted between 7/1997 and 9/2003. Detailed mental-
health resource utilization was systematically abstracted from medical records and augmented with
patients' self report. Medication possession ratio (MPR) with any antipsychotic in the 6 months
prior to enrollment was used to categorize patients as: adherent (MPR ≥ 80%, N = 1758), partially
adherent (MPR ≥ 60% < 80%, N = 36), or non-adherent (MPR < 60%, N = 216). Group comparisons
employed propensity score-adjusted bootstrap re-sampling methods with 1000 iterations, adjusting
for baseline patient demographic and clinical characteristics identified a priori.
Results: Adherent patients had a lower rate of psychiatric hospitalization compared with partially
adherent and non-adherent patients (p < 0.001) and were more likely than non-adherent to engage
in group therapy, individual therapy, and medication management. Most patients (92.0%) who were
adherent in the 6 months prior to hospital admission continued to be adherent 6 months following
hospitalization. However, 75.0% of previously partially adherent became adherent, and 38.7% of
previously non-adherent became adherent following hospitalization.
Conclusion: Adherence is associated with lower utilization of acute care services and greater
engagement in outpatient mental-health treatment. Adherence is a potentially dynamic
phenomenon, which may improve, at least temporarily, following patients' psychiatric
hospitalizations.
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Background
Schizophrenia is often a persistent, debilitating, and
costly disorder requiring diverse healthcare resources to
manage the illness. Although adherence with antipsy-
chotic medications is critical for reducing the risk of
relapse and enhancing long-term functional outcomes
[1], non-adherence is typically found in about 40%–50%
of patients with schizophrenia [2].
Non-adherence is associated with increased risk of relapse
and hospitalization [3-7], the most expensive health serv-
ice component in the treatment of schizophrenia [8].
While the link between non-adherence and psychiatric
hospitalization is well documented, little is known about
the relationships between adherence and utilization of
other mental-health resources in the management of
schizophrenia, such as emergency services, partial hospi-
talization, and various outpatient services. The complexi-
ties of the illness and the heterogeneity of mental-health
outpatient services call for data-driven analyses character-
izing the use of specific categories of mental-health
resources [8]. Outpatient services, including individual
therapy, psychosocial and rehabilitation group therapy,
case management, and medication management, may be
conceptualized as "expectable" healthcare resources
because the management of schizophrenia requires com-
prehensive and continuous care. Lack of expected outpa-
tient resource utilization may signal that a patient is not
engaged in the treatment plan and may therefore be non-
adherent with medication and at increased risk of relapse
and hospitalization.
Recent research also suggests that adherence is not an "all
or none" phenomenon as many patients appear to be par-
tially adherent with treatment, failing to take their medi-
cations as prescribed and having gaps in medication
intake [3,9,10]. Therefore, studies now often evaluate cat-
egories of adherence, including partial adherence, non-
adherence and full adherence [5,6,9,10]. Furthermore, the
stability of medication adherence over time has received
sparse attention, as has the potential impact of hospitali-
zation on medication adherence level following hospital
discharge. Although adherence has often been assumed to
be a stable patient characteristic, recent data suggest that
adherence level is not fixed [6,10], with non-adherent
patients displaying less stable adherence status compared
with adherent patients [6].
To expand on previous research and provide new infor-
mation about the relationship between adherence and
resource utilization, a type of information that is espe-
cially relevant for policy makers and other mental-health
decision makers, this study used data from a large, pro-
spective, naturalistic, non-interventional multi-site study
of patients treated in the United States for schizophrenia
(US Schizophrenia Care and Assessment Program; US-
SCAP) [6,11,12] to: (1) compare utilization of various
types of mental-health services over a 1-year period by
patients' recent (6 months prior to enrollment) level of
adherence with antipsychotic medications; and (2) assess
whether psychiatric hospitalization impacts subsequent
adherence levels in usual care.
Methods
Participants in US-SCAP (N = 2327), which was con-
ducted between July 1997 and September 2003, were
enrolled from large systems of care across the United
States. Inclusion criteria were broad: schizophrenia,
schizoaffective disorder, and/or schizophreniform disor-
der based on the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV) criteria as noted in
patients' medical records (no structured diagnostic inter-
views were conducted at study entry), and ≥ 18 years old.
The study protocol was reviewed and approved by the
Institutional Review Board (IRB) at each site, and written
informed consent was obtained from all participants. Fur-
ther details about US-SCAP can be found elsewhere
[6,11,12]. Patient characteristics at enrollment were
assessed using a structured interview, medical record
information, and standard psychiatric rating scales,
including the Positive and Negative Syndrome Scale
(PANSS) [13], the Global Assessment of Functioning scale
(GAF) [14], Simpson-Angus Scale for extrapyramidal side
effects [15], Abnormal Involuntary Movement Scale
(AIMS) [16], the Quality of Life Scale [17], and the SCAP-
Health Questionnaire (SCAP-HQ), a health questionnaire
developed and validated for the study [18].
Mental-health resource utilization during the 1 year fol-
lowing study enrollment was systematically abstracted
from medical records by trained examiners, using an
abstraction form developed for this study. Patient-
reported use of emergency psychiatric services on the
SCAP-HQ was also used to help identify use of emergency
services if this medical record information was missing.
Antipsychotic medication use and adherence levels were
derived from prescription information in patients' medi-
cal records. Medication possession ratios (MPRs) for the 6
months prior to enrollment were computed. MPR was
defined as the sum of days with medication, divided by
the number of days in the observation period, 6 months
prior to enrollment. Consistent with prior research [5,19],
the MPR for each patient was categorized as: adherent
(MPR ≥ 80%), partially adherent (MPR ≥ 60% < 80%),
and non-adherent (MPR < 60%).
The current analysis used data of US-SCAP participants
who had resource utilization information for the 1 year
following enrollment and antipsychotic medication infor-
mation for the 6 months prior to enrollment. For statisti-BMC Research Notes 2009, 2:6 http://www.biomedcentral.com/1756-0500/2/6
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cal analyses, χ2 tests, ANOVA, and Kruskal-Wallis tests
were used to test for overall differences across adherence
levels in patient characteristics at enrollment, the mean
number of service contacts, and the proportion of patients
with any of the following resource-utilization types: inpa-
tient psychiatric hospitalization, emergency service, psy-
chiatrist contact ("medication management"), partial
hospitalization, psychosocial group therapy, individual
therapy, and case management/Assertive Community
Treatment (ACT).
Group comparisons (adherent vs non-adherent, adherent
vs partially adherent, partially adherent vs non-adherent)
were performed using propensity score-adjusted boot-
strap re-sampling methods with 1000 iterations, adjusting
for baseline patient demographic and clinical characteris-
tics identified a priori. Propensity score stratification was
used to adjust for potential confounding factors not
attributable to adherence status. Bootstrap resampling
was used to allow for a non-parametric assessment of
mean outcomes in resource utilization. The propensity
score for each patient was estimated with a logistic regres-
sion model with the following apriori selected covariates:
age, gender, race, illness duration, study site, comorbid
substance use disorder, schizoaffective disorder, comor-
bid personality disorder, comorbid borderline intelli-
gence or mental retardation, uninsured, inpatient status at
enrollment, and time elapsed between start of US-SCAP
enrollment and the start date of each patient's study year.
The estimated propensity scores were grouped into 5
strata based on quintiles, and bootstrap resampling was
performed in a balanced fashion within each group across
the propensity score strata. For example, each bootstrap
replication for the non-adherent group would include
approximately 43 re-sampled observations from each of
the 5 strata. Pair-wise group comparisons on resource uti-
lization were reported if the overall differences across the
3 groups were significant (p < 0.05).
Results
Patient characteristics and adherence levels
Of 2327 US-SCAP participants, 2010 (86.4%) had health-
care resource utilization for 1 year after study enrollment
and comprised the analytic sample.
Patient characteristics at enrollment are presented in Table
1. Most participants were outpatients, male, and in their
early 40s. About one third were African American and a
small proportion was uninsured. Patients were ill for 2
decades, on average, and mostly moderately ill (per
PANSS scores), with an impoverished quality of life (per
Quality of Life scores). There were moderate rates of
comorbid substance abuse disorder, personality disorder,
and borderline intelligence or mental retardation. Partici-
pants also manifested mild-to-moderate levels of extrapy-
ramidal symptoms and involuntary body movements
(per Simpson-Angus and AIMS scores).
During the 6 months prior to enrollment, most patients
were deemed adherent (87.5%). The rest were non-adher-
ent (10.7%) or partially adherent (1.8%). Patients who
were adherent prior to enrollment were significantly older
than partially or non-adherent. African-American patients
and uninsured patients were more likely to be partially
adherent than adherent or non-adherent. There was a > 3-
fold higher rate of hospitalization at enrollment among
non-adherent compared with partially adherent or adher-
ent. There were also higher rates of comorbid substance
abuse disorder among patients with lower adherence lev-
els (Table 1).
Table 1: Baseline patient characteristics by level of medication adherence in the 6 months prior to enrollment (N = 2010)
Characteristic Adherent
(n = 1758)
Partially adherent
(n = 36)
Non-adherent
(n = 216)
p-value
Age at baseline, mean ± SD years 42.4 ± 11.0 38.5 ± 9.3 39.9 ± 11.6 0.007
Male, n (%) 1075 (61.2) 21 (58.3) 135 (62.5) 0.870
African American, n (%) 651 (37.2) 21 (58.3) 77 (36) 0.031
Schizoaffective diagnosis, n (%) 583 (33.2) 13 (36.1) 66 (30.6) 0.684
Illness duration, mean ± SD years 21.7 ± 11.4 19.7 ± 10.0 20.3 ± 12.7 0.136
Uninsured, n (%) 105 (6.1) 5 (13.9) 21 (10.0) 0.020
PANSS total score, mean ± SD 70.3 ± 18.6 72.2 ± 22.4 70.9 ± 17.1 0.593
Quality of Life Scale, total score, mean ± SD 60.0 ± 22.3 58.9 ± 21.6 61.7 ± 22.4 0.781
Hospitalized at enrollment, n (%) 52 (2.96) 1 (2.78) 23 (10.65) < 0.001
Comorbid substance abuse disorder, n (%) 483 (27.47) 12 (33.33) 78 (36.11) 0.024
Comorbid personality disorder diagnosis, n (%) 268 (15.24) 2 (5.56) 36 (16.67) 0.228
Comorbid borderline intelligence/mental retardation, n (%) 176 (10.01) 5 (13.89) 13 (6.02) 0.118
Simpson-Angus total score, mean ± SD 4.34 ± 4.08 4.00 ± 4.17 4.15 ± 4.08 0.547
AIMS total score, mean ± SD 3.35 ± 4.13 2.94 ± 3.73 2.51 ± 3.14 0.137
SD = standard deviation; PANSS = Positive and Negative Syndrome Scale; AIMS = Abnormal Involuntary Movement ScaleBMC Research Notes 2009, 2:6 http://www.biomedcentral.com/1756-0500/2/6
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Utilization of acute care services
During the 1 year following enrollment, adherent patients
in the 6 months prior to enrollment were significantly less
likely to have a psychiatric hospitalization (17.1%) com-
pared with partially adherent (30.6%) and non-adherent
patients (29.6%) (p < 0.05) (Table 2). Adherent partici-
pants also had about half as many inpatient admissions
(0.28, 0.64 and 0.55 [p < 0.05 adherent vs partially and vs
non-adherent]), and fewer total days hospitalized (8.8 vs
32.0 and 17.6 days [p < 0.05 adherent vs partially adher-
ent]) (Table 3). The lowest mean number of emergency
service contacts was observed for adherent patients, with
statistically significant differences between adherent and
non-adherent (p < 0.05) (Table 3). There were no signifi-
cant differences in partial hospitalization (proportion of
patients or mean number of contacts) by level of adher-
ence (Table 2 and Table 3).
Utilization of non-acute care services
Participants who were adherent prior to enrollment were
significantly more likely in the 1 year following enroll-
ment to engage in outpatient treatment, including psy-
chosocial group therapy, individual therapy, and
medication management ("psychiatrist contact") than
non-adherent patients (Table 2). The frequency in which
these outpatient services were used did not significantly
differ by adherence level (Table 3) with the exception of
contacts with psychiatrists, which were significantly fewer
for non-adherent compared to adherent and partially
adherent patients.
Change in adherence level after hospitalization
Among 315 patients who were hospitalized, 276 patients
were adherent 6 months prior to hospitalization, 8 were
partially adherent, and 31 were non-adherent. Most
patients who were adherent 6 months before hospitaliza-
tion were also adherent 6 months afterward (92.0%)
(Table 4). Most patients who were partially adherent
before being hospitalized were adherent afterward
(75.0%), and some patients who were non-adherent
before being hospitalized were adherent (38.7%) or par-
tially adherent (9.7%) afterward.
Discussion
In this large, prospective, naturalistic, non-interventional
study of patients treated for schizophrenia across the
United States, patients who were deemed adherent imme-
diately before enrollment had enhanced treatment out-
comes in the subsequent year. Adherent patients
evidenced a significantly lower risk of psychiatric hospi-
talization and better engagement in outpatient mental
health care. Further, patient adherence proved to be a
dynamic, rather than a static, phenomenon that appeared
to be influenced by the experience of psychiatric hospital-
ization. Although most patients who were adherent
before hospitalization continued to be adherent after-
ward, a large proportion of patients who were previously
partially adherent or non-adherent became adherent in
the 6 months after hospital discharge.
Current findings show that recently adherent patients had
about half as many psychiatric hospitalizations and 2 to 4
times fewer total days hospitalized compared with par-
tially and non-adherent patients. These findings are con-
sistent with previous research [3-7]. Furthermore, recently
adherent patients were more likely to be engaged in vari-
ous outpatient treatment than non-adherent patients, sug-
gesting that increased outpatient contact may decrease the
risk of medication non-adherence [20].
Most patients in this study (87.5%) were deemed adher-
ent and the rate of partial or non-adherence (12.5%) was
lower than the 40% to 50% non-adherence rates reported
in some previous studies but was broadly consistent with
data reported in some other studies [3,20] in which non-
adherence rates ranged between 15% and 20%.
Table 2: Proportions of patients using inpatient and outpatient healthcare resource components during the 1 year after study 
enrollment, by treatment adherence level at enrollment
Resource component Adherent
(n = 1758)
Partially Adherent
(n = 36)
Non-adherent
(n = 216)
Hospitalizationa 17.1% 30.6% 29.6%
Emergency Services 20.6% 25.0% 26.9%
Partial Hospitalization 23.6% 30.6% 21.8%
Psychiatrist Contactb 90.8% 91.7% 64.8%
Psychosocial Groupc 47.1% 47.2% 35.2%
Individual Therapyc 78.9% 72.2% 60.2%
Case Management/ACT 61.6% 52.8% 53.7%
ACT = Assertive Community Treatment
a Overall p < 0.05; significant difference between adherent vs partially and non-adherent (p < 0.05)
b Overall p < 0.05; significant difference between non-adherent vs adherent and partially adherent (p < 0.05)
c Overall p <0.05; significant difference between adherent vs non-adherent (p < 0.05)BMC Research Notes 2009, 2:6 http://www.biomedcentral.com/1756-0500/2/6
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In the present study, treatment adherence was also found
to change from the 6 months pre-hospitalization to the 6
months post hospitalization, suggesting that adherence is
a dynamic phenomenon. The reasons for the observed
changes are unclear, but may be driven by increased atten-
tion to patient's medication management by members of
the treatment team (e.g., case manager, psychiatrist), thus
increasing intensity of medication management efforts
post discharge, and leading, indirectly, to increased
patients' MPR. The increased adherence post hospital dis-
charge may also reflect involuntary commitment (com-
pulsory treatment orders) to outpatient treatment for
some patients. However, this information was not cap-
tured in our study. Another potential, but less likely,
explanation is that hospitalization reflects a "teachable
moment" for the patient, thereby leading to increased
adherence with medication post hospital discharge.
Current findings need to be evaluated in the context of the
study limitation. First is the naturalistic nature of the
study. Although generally considered a strength, the
observational nature introduces selection biases. We uti-
lized propensity scoring to statistically adjust for selection
bias; however, such methods adjust only for known and
measured confounds and cannot address the prospect
that the results may be partly attributed to or altered by
unknown or unmeasured group differences. Second, cur-
rent findings may not be generalizable to patients with
private insurance because public payers covered health-
care services for almost all US-SCAP participants [11].
Third, adherence was evaluated by prescription informa-
tion in patients' medical records, which may not accu-
rately reflect medication prescription fills/refills or actual
medication-taking behavior. Finally, the subgroup of par-
tially adherent patients was small (n = 36), thus poten-
tially limiting the conclusiveness of findings in this group.
Conclusion
In the usual treatment of schizophrenia patients, medica-
tion adherence is associated with a lower risk of psychiat-
ric hospitalization and with greater engagement in
outpatient mental-health treatment. Adherence also
appears to be a dynamic phenomenon, which may
improve, at least temporarily, following patients' psychi-
atric hospitalizations. Current findings underscore the
clinical and economic value of medication adherence, the
need to separately assess acute-care and non-acute care
resource utilization, and the realization that partially
adherent patients, not only the non-adherent patients,
should be targeted for adherence-promoting interven-
tions.
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